Poster 27: EFFICACY AND TOLERABILITY OF JANUS KINASE INHIBITORS IN
MYELOFIBROSIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Léa Sureau, Corentin Orvain, Jean-Christophe Ianotto, Valérie Ugo, Jean-Jacques
Kiladjian, Damien Luque Paz, Jérémie Riou
Poster 28: EXTREME PERIPHERAL ERYTHROBLASTOSIS AND HEMOGLOBIN LEVEL
INCREASE AS A DEBUT OF LEUKEMIC TRANSFORMATION OF ESSENTIAL
THROMBOCYTHEMIA
Gergana Tsvetkova, Evgueniy Hadjiev
Poster 29: TRIPLE-NEGATIVE PRIMARY MYELOFIBROSIS WITH GRADE 3
THROMBOCYTOPENIA SUCCESSFULLY MANAGED WITH LOW DOSE
RUXOLUTINIB
Hugo Verdelho Parreira, Mariana Leal Fernandes, Paula Sousa e Santos, Patrícia
Ribeiro
Poster 30: REAL-WORLD SURVIVAL AMONG PATIENTS WITH INTERMEDIATE- TO HIGH-RISK
MYELOFIBROSIS IN THE UNITED STATES: IMPACT OF RUXOLITINIB
APPROVAL
Srdan Verstovsek, Shreekant Parasuraman, Jingbo Yu, Anne Shah, Shambhavi Kumar,
Ann Xi, Claire Harrison
Poster 31: CHANGES IN THE INCIDENCE AND OVERALL SURVIVAL OF PATIENTS WITH
MYELOPROLIFERATIVE NEOPLASMS BETWEEN 2002 AND 2016 IN THE UNITED
STATES
Srdan Verstovsek, Jingbo Yu, Robyn M. Scherber, Sumit Verma, Christopher Dieyi,
Shreekant Parasuraman
Poster 32: CML RESPONSE TO THERAPY IN BRITISH COLUMBIA - A TEN YEAR
RETROSPECTIVE ANALYSIS
Sean Young, Darko Curman, Elaine Law, Amadea Kristanti, Sarah Egli, Tracy Tucker, Ian
Bosdet, Donna Forrest, Stephen Nantel, Aly Karsan, Stephen Yip